Skip to content

A randomized controlled trial of modular psychotherapy for autistic youth

Empowering autistic youth with personalized intervention: a randomized controlled trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN34266422
Enrollment
148
Registered
2025-10-21
Start date
2025-11-03
Completion date
Unknown
Last updated
2025-11-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autism spectrum disorder Mental and Behavioural Disorders

Interventions

The experimental group will receive Schema-, Emotion-, and Behavior-Focused Therapy (SEBASTIEN) for youth with autism. Youth randomized to SEBASTIEN will receive 16 x 60 minutes individually tailored

Sponsors

Innlandet Hospital Trust
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Clinically confirmed autism diagnosis 2. 6 to 18 years of age 3. Autism symptoms above the clinical cutoff (measured with the Social Responsiveness Scale [SRS-2])

Exclusion criteria

Exclusion criteria: 1. Intellectual disability (i.e., IQ <70) 2. Severe hearing impairment (without correction)

Design outcomes

Primary

MeasureTime frame
Top three problems of the parent- and self-reported autism-adapted Youth Top Problem scale (Wood et al., 2022) collected at baseline, post-treatment, and 3-, 12-, and 24-months follow-up. The YTP will also be collected weekly from baseline to post-treatment (20 weeks) to inform treatment and for secondary analysis

Secondary

MeasureTime frame
1. Internalizing and externalizing problems measured using the Brief Problem Checklist (BPC; Chorpita et al., 2010) at baseline, post-treatment, and 3-, 12-, and 24-months follow-up 2. Quality of life measured using the KIDSCREEN-10 (Ravens-Sieberer et al., 2010) at baseline, post-treatment, and 3-, 12-, and 24-months follow-up 3. Autism symptoms rated by parents measured using the Social Responsiveness Scale (SRS-2; Constantino & Gruber, 2005) at baseline, post-treatment, and 3-, 12-, and 24-months follow-up

Countries

Norway

Contacts

Public ContactStian Orm
stian.orm@inn.no+47 (0)97154591

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026